Aspire Biopharma secures commitment letter for up to $22.5 million DCS acquisition loan
PUBT · 1d ago
Share
Listen to the news
- Aspire Biopharma entered a letter of intent dated April 15, 2026 to buy Dura Control Systems (DCS) for USD 30 million in cash.
- DCS is described as a global automotive driver control systems supplier with FY2025 revenue above USD 200 million.
- DCS delivered more than USD 20 million of adjusted EBITDA on that revenue base, on an unaudited basis.
- Aspire secured a commitment letter for a senior secured credit facility of up to USD 22.5 million to finance the proposed acquisition.
- Facility is structured as a five-year term loan priced at 325 basis points over one-month term SOFR.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aspire Biopharma Holdings Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 202604200830ACCESSWRNAPR_____1158888) on April 20, 2026, and is solely responsible for the information contained therein.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending
No content on the Webull website shall be considered a recommendation or solicitation for the purchase or sale of securities, options or other investment products. All information and data on the website is for reference only and no historical data shall be considered as the basis for judging future trends.
Copyright © 2026 Webull. All Rights Reserved